Bone metabolism and the cardiometabolic syndrome: pathophysiologic insights.

Item

http://www.wikidata.org/entity/Q43541810

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Bone metabolism and the cardiometabolic syndrome: pathophysiologic insights.

@en

Bone metabolism and the cardiometabolic syndrome: pathophysiologic insights.

@nl

type

Item

label

Bone metabolism and the cardiometabolic syndrome: pathophysiologic insights.

@en

Bone metabolism and the cardiometabolic syndrome: pathophysiologic insights.

@nl

prefLabel

Bone metabolism and the cardiometabolic syndrome: pathophysiologic insights.

@en

Bone metabolism and the cardiometabolic syndrome: pathophysiologic insights.

@nl

P1476

Bone metabolism and the cardiometabolic syndrome: pathophysiologic insights.

@en

P2093

Samy I McFarlane

http://www.w3.org/2001/XMLSchema#string

P2860

Differential effect of obesity on bone mineral density in White, Hispanic and African American women: a cross sectional study

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Atherogenic diet and minimally oxidized low density lipoprotein inhibit osteogenic and promote adipogenic differentiation of marrow stromal cells

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

The metabolic syndrome--a new worldwide definition

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment.

Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond.

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.

Diabetes Mellitus: Does it Affect Bone?

P304

53-57

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.0197-3118.2006.05457.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6163289

http://www.w3.org/2001/XMLSchema#string

P698

17675897

http://www.w3.org/2001/XMLSchema#string

P921

pathophysiology